Inflammation-related prognostic markers in resected hepatocellular carcinoma.

Fiche publication

Date publication

décembre 2023

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas , Dr LUPBERGER Joachim , Pr PESSAUX Patrick

Tous les auteurs :
Giannone F, Slovic N, Pessaux P, Schuster C, Baumert TF, Lupberger J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38144522

Résumé

Hepatocellular carcinoma is usually detected late and therapeutic options are unsatisfactory. Despite marked progress in patient care, HCC remains among the deadliest cancers world-wide. While surgical resection remains a key option for early-stage HCC, the 5-year survival rates after surgical resection are limited. One reason for limited outcomes is the lack of reliable prognostic biomarkers to predict HCC recurrence. HCC prognosis has been shown to correlate with different systemic and pathological markers which are associated with patient survival and HCC recurrence. Liver inflammatory processes offer a large variety of systemic and pathological markers which may be exploited to improve the reliability of prognosis and decision making of liver surgeons and hepatologists. The following review aims to dissect the potential tools, targets and prognostic meaning of inflammatory markers in patients with resectable HCC. We analyze changes in circulant cellular populations and assess inflammatory biomarkers as a surrogate of impaired outcomes and provide an overview on predictive gene expression signatures including inflammatory transcriptional patterns, which are representative of poor survival in these patients.